Lonza has officially opened a new capsule-based development facility at its Colmar, France site.
The base will offer a range of drug development services, which Lonza has named under the umbrella term, Innovaform.
The novel facility will act as a centre of excellence for developing manufacturing and delivery solutions for both oral and pulmonary administration.
For a therapeutic to be successful, the APIs in its formulation must be sufficiently absorbed in the gastrointestinal tract.
Therefore, developing formulation strategies that solve these challenges are essential.
Lonza have taken this on by creating the Innovaform Accelerator, which will provide its customers with access to a team of experts and a range of technology platforms.
This service will allow drug developers to enhance their formulation and encapsulation technologies, while also providing the potential for companies to receive customised capsules through the Capsugel® Enprotect® platform.
Lonza's team of experts can provide support with a number of aspects of development, including:
- Formulation development
- Capsule customisation
- Selection of encapsulation process parameters
- Compatibility studies
- Controlled release testing
- Scale-up manufacturing assessments
The new offering targets small molecules and extends to oral peptides, proteins, monoclonal antibodies and nucleic acid-based therapeutics.
Christian Seufert, President, Capsules & Health Ingredients, Lonza, commented: “The Innovaform Innovation and Formulation Accelerator represents a unique solution for drug developers seeking to solve complex dosage form and delivery challenges through innovation."
"This service extension plays a critical role in our commitment to innovating together with our customers and provides our customers with the ability to accelerate their development timelines and reduce scale-up and manufacturing costs.”
